Pathophysiology and Pharmacological Treatment of Gastroesophageal Reflux Disease
- 1 July 2000
- journal article
- review article
- Published by S. Karger AG in Digestive Diseases
- Vol. 18 (2) , 93-102
- https://doi.org/10.1159/000016970
Abstract
Gastroesophageal reflux disease (GERD) is one of the most common diagnoses in a gastroenterologist’s practice. Gastroesophageal reflux describes the retrograde movement of gastric contents through the lower esophageal sphincter (LES) to the esophagus. It is a common, normal phenomenon which may occur with or without accompanying symptoms. Symptoms associated with GERD include heartburn, acid regurgitation, noncardiac chest pain, dysphagia, globus pharyngitis, chronic cough, asthma, hoarseness, laryngitis, chronic sinusitis and dental erosions. The introduction of fiberoptic instruments and ambulatory devices for continuous monitoring of esophageal pH (24-hour pH monitoring) has led to great improvement in the ability to diagnose reflux disease and reflux-associated complications. The development of pathological reflux and GERD can be attributed to many factors. Pathophysiology of GERD includes incompetent LES because of a decreased LES pressure, transient lower esophageal sphincter relaxations (TLESRs) and deficient or delayed esophageal acid clearance. Uncomplicated GER may be treated by modification of life style and eating habits in an early stage of GERD. The various agents currently used for treatment of GERD include mucoprotective substances, antacids, H2 blockers, prokinetics and proton pump inhibitors. Although these drugs are effective, they do not necessarily influence the underlying causes of the disease by improving the esophageal clearance, increasing the LESP or reducing the frequency of TLESRs. The following article gives an overview regarding current concepts of the pathophysiology and pharmacological treatment of GERD.Keywords
This publication has 6 references indexed in Scilit:
- Outcome of open antireflux surgery as assessed in a nordic multicentre prospective clinical trialBritish Journal of Surgery, 2003
- Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal AdenocarcinomaNew England Journal of Medicine, 1999
- The Esophagogastric JunctionNew England Journal of Medicine, 1997
- A Comparison of Five Maintenance Therapies for Reflux EsophagitisNew England Journal of Medicine, 1995
- The 5-HT4 receptor: naughty, but niceTrends in Pharmacological Sciences, 1989
- DomperidoneGeneral Pharmacology: The Vascular System, 1988